BioMaxima S.A. (FRA:944)

Germany · Delayed Price · Currency is EUR

1.884

-0.020 (-1.05%)

Last updated: Oct 23, 2026, 3:25 PM CEST

Market Cap	9.36M -28.6%
Revenue (ttm)	14.11M +6.3%
Net Income	188.19K +15.2%
EPS	0.04 +15.8%
Shares Out	n/a
PE Ratio	43.04
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6
Open	1.922
Previous Close	1.904
Day's Range	1.884 - 1.922
52-Week Range	1.798 - 3.350
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About BioMaxima

BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which include real time PCR, nucleic acid isolation, NA and PCR electrophoresis, protein electrophoresis, enzymes, antibiotics, agaroses and molecular biology media, media and buffers for in vi... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 1997

Employees 143

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 944

Financial Performance

In 2025, BioMaxima's revenue was 60.90 million, an increase of 15.24% compared to the previous year's 52.85 million. Earnings were 105,000, a decrease of -80.37%.

Financial numbers in PLN Financial Statements